\-\ Texto\\:\\ \ \(0\)\
\-\ asymptomatic\\ right\\-sided\\ abdominal\\ mass\\.\ \(0\)\
\-\ 6\\ weeks\\ of\\ neoadjuvant\\ chemotherapy\\ comprised\\ of\\ vincristine\\,\\ dactinomycin\\,\\ doxorubicin\\ \\(dd4a\\)\\ followed\\ by\\ right\\ nephrectomy\\.\ \(0\)\
\-\ \\‚\\Ä\\¢\\ initial\\ study\\:\ \(0\)\
\-\ large\\ right\\-sided\\ renal\\ mass\\ \\(12\\.2cm\\ ap\\ x\\ 10\\.6cm\\ trans\\ x\\ 14\\.1cm\\ cc\\)\\.\\ predominantly\\ hypodense\\ w\\/\\ areas\\ of\\ heterogeneity\\.\\ \\ possible\\ cystic\\ degeneration\\ along\\ superior\\ border\\.\ \(0\)\
\-\ classic\\ \\‚\\Ä\\úclaw\\ sign\\‚\\Ä\\ù\\ demonstrating\\ renal\\ origination\\.\ \(0\)\
\-\ significant\\ mass\\ effect\\ on\\ liver\\,\\ pancreas\\,\\ and\\ inferior\\ vena\\ cava\\.\ \(0\)\
\-\ non\\-opacification\\ of\\ right\\ renal\\ vein\\ and\\ mass\\ effect\\ on\\ ivc\\ limit\\ evaluation\\ for\\ tumor\\ thrombosis\\.\ \(0\)\
\-\ right\\ lower\\ lobe\\ ground\\ glass\\ opacity\\ \\(3mm\\ x\\ 5mm\\)\\.\\ \\ ddx\\ includes\\ metastatic\\,\\ atelectasis\\,\\ or\\ infection\\.\ \(0\)\
\-\ \\‚\\Ä\\¢\\ after\\ 6\\ weeks\\ doxorubicin\\ \\(dd4a\\)\\ therapy\\:\ \(0\)\
\-\ decrease\\ in\\ right\\ renal\\ mass\\ size\\ \\(7\\.3cm\\ ap\\ x\\ 8\\.4cm\\ trans\\ x\\ 11\\.7cm\\ cc\\)\\.\ \(0\)\
\-\ increased\\ calcification\\ and\\ heterogenicity\\ of\\ mass\\.\ \(0\)\
\-\ continued\\ mass\\ effect\\ on\\ liver\\,\\ adjacent\\ ivc\\,\\ and\\ right\\ renal\\ vein\\.\ \(0\)\
\-\ ivc\\ and\\ right\\ renal\\ vein\\ grossly\\ patent\\.\ \(0\)\
\-\ resolution\\ of\\ previously\\ noted\\ right\\ lower\\ lobe\\ lung\\ mass\\.\ \(0\)\
\-\ internal\\ reproductive\\ organs\\ within\\ normal\\ limits\\ for\\ age\\.\ \(0\)\
\-\ wilms\\ tumor\ \(0\)\
\-\ \\‚\\Ä\\¢\\ wilms\\ tumor\ \(0\)\
\-\ \\‚\\Ä\\¢\\ neuroblastoma\ \(1\)\
\-\ \\‚\\Ä\\¢\\ multilocular\\ cystic\\ nephroma\ \(0\)\
\-\ \\‚\\Ä\\¢\\ mesoblastic\\ nephroma\ \(0\)\
\-\ \\‚\\Ä\\¢\\ renal\\ cell\\ carcinoma\ \(1\)\
\-\ 30\\ month\\ old\\ girl\\ with\\ right\\-sided\\ abdominal\\ mass\\.\ \(1\)\
\-\ this\\ case\\ demonstrates\\ the\\ classic\\ \\"claw\\ sign\\"\\ expected\\ for\\ tumor\\ originating\\ from\\ the\\ kidney\\.\\ \\ also\\ demonstrated\\ the\\ significant\\ mass\\ effect\\ that\\ wilms\\ tumors\\ can\\ have\\ on\\ intra\\-abdominal\\ organs\\ and\\ vessels\\.\\ \\ finally\\,\\ benefits\\ on\\ neoadjuvant\\ therapy\\ was\\ appreciated\\ with\\ decreased\\ tumor\\ burden\\ prior\\ to\\ tumor\\ removal\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\-\\:\\ 0\\.07170467276082562\ \(0\)\
\-\ renal\\:\\ 0\\.06395846564486293\ \(0\)\
\-\ dd4a\\:\\ 0\\.06274390337342703\ \(0\)\
\-\ wilms\\:\\ 0\\.056467877929007156\ \(0\)\
\-\ x\\:\\ 0\\.05016132269301561\ \(0\)\
\-\ trans\\:\\ 0\\.049991166937640164\ \(0\)\
\-\ ivc\\:\\ 0\\.04860681722695925\ \(0\)\
\-\ neoadjuvant\\:\\ 0\\.047105294282066036\ \(0\)\
\-\ claw\\:\\ 0\\.04567703310439948\ \(0\)\
\-\ nephroma\\:\\ 0\\.04505773504753379\ \(0\)\
\-\ right\\-sided\\:\\ 0\\.04453161058532163\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.043960577183994584\ \(0\)\
\-\ effect\\:\\ 0\\.04306844488354797\ \(0\)\
\-\ tumor\\:\\ 0\\.04253876800592479\ \(0\)\
\-\ mass\\:\\ 0\\.04229398601236885\ \(0\)\
\-\ \\‚\\Ä\\¢\\:\\ 0\\.03903594470167692\ \(0\)\
\-\ organs\\:\\ 0\\.03490032326361816\ \(0\)\
\-\ vein\\:\\ 0\\.03300996429196566\ \(0\)\
\-\ cc\\:\\ 0\\.03260791401686291\ \(0\)\
\-\ 12\\.2cm\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ 10\\.6cm\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ 14\\.1cm\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ non\\-opacification\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ 8\\.4cm\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ 11\\.7cm\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ heterogenicity\\:\\ 0\\.031371951686713515\ \(0\)\
\-\ dactinomycin\\:\\ 0\\.027462299413873268\ \(0\)\
\-\ origination\\:\\ 0\\.027462299413873268\ \(0\)\
\-\ 7\\.3cm\\:\\ 0\\.027462299413873268\ \(0\)\
\-\ comprised\\:\\ 0\\.02564441463178789\ \(0\)\
\-\ reproductive\\:\\ 0\\.023971803851553956\ \(0\)\
\-\ mesoblastic\\:\\ 0\\.023971803851553956\ \(0\)\
\-\ classic\\:\\ 0\\.023304305187246063\ \(0\)\
\-\ right\\:\\ 0\\.02246057638353351\ \(0\)\
\-\ ap\\:\\ 0\\.022243124339092084\ \(0\)\
\-\ heterogeneity\\:\\ 0\\.021980288591997292\ \(0\)\
\-\ burden\\:\\ 0\\.021734762358947644\ \(0\)\
\-\ multilocular\\:\\ 0\\.02150508790650077\ \(0\)\
\-\ sign\\:\\ 0\\.021070793606861715\ \(0\)\
\-\ liver\\:\\ 0\\.02096954811980586\ \(0\)\
\-\ limit\\:\\ 0\\.020710982741681518\ \(0\)\
\-\ vincristine\\:\\ 0\\.02053735226421023\ \(0\)\
\-\ intra\\-abdominal\\:\\ 0\\.020371800607146554\ \(0\)\
\-\ 3mm\\:\\ 0\\.02006215157871371\ \(0\)\
\-\ benefits\\:\\ 0\\.02006215157871371\ \(0\)\
\-\ 5mm\\:\\ 0\\.019151356652958546\ \(0\)\
\-\ finally\\:\\ 0\\.018426805210818905\ \(0\)\
\-\ 6\\:\\ 0\\.018164556308717966\ \(0\)\
\-\ originating\\:\\ 0\\.018156392730470428\ \(0\)\
\-\ glass\\:\\ 0\\.017595435633660523\ \(0\)\
\-\ cystic\\:\\ 0\\.017541869802503617\ \(0\)\
\-\ weeks\\:\\ 0\\.017261763394314223\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.01724279896944618\ \(0\)\
\-\ ground\\:\\ 0\\.016742507330224865\ \(0\)\
\-\ lobe\\:\\ 0\\.016365304967427288\ \(0\)\
\-\ significant\\:\\ 0\\.016354783993268493\ \(0\)\
\-\ therapy\\:\\ 0\\.01626078858534244\ \(0\)\
\-\ hypodense\\:\\ 0\\.016202272408986414\ \(0\)\
\-\ vena\\:\\ 0\\.016103412750242373\ \(0\)\
\-\ ddx\\:\\ 0\\.01605499405965241\ \(0\)\
\-\ cava\\:\\ 0\\.016007225304022023\ \(0\)\
\-\ grossly\\:\\ 0\\.01596008926576572\ \(0\)\
\-\ w\\/\\:\\ 0\\.015777550851575145\ \(0\)\
\-\ pancreas\\:\\ 0\\.01556180486646328\ \(0\)\
\-\ degeneration\\:\\ 0\\.015438368717040182\ \(0\)\
\-\ neuroblastoma\\:\\ 0\\.015203642853012435\ \(0\)\
\-\ abdominal\\:\\ 0\\.015202272157452778\ \(0\)\
\-\ patent\\:\\ 0\\.014983445686755895\ \(0\)\
\-\ expected\\:\\ 0\\.01480981520928461\ \(0\)\
\-\ appreciated\\:\\ 0\\.01480981520928461\ \(0\)\
\-\ atelectasis\\:\\ 0\\.014612057731865353\ \(0\)\
\-\ border\\:\\ 0\\.014486072226346078\ \(0\)\
\-\ predominantly\\:\\ 0\\.01424674045763018\ \(0\)\
\-\ opacity\\:\\ 0\\.014217924762852175\ \(0\)\
\-\ decrease\\:\\ 0\\.013915457813267147\ \(0\)\
\-\ lower\\:\\ 0\\.01367873358977838\ \(0\)\
\-\ demonstrating\\:\\ 0\\.01320132722443387\ \(0\)\
\-\ resolution\\:\\ 0\\.013116084373820017\ \(0\)\
\-\ continued\\:\\ 0\\.013095088921410094\ \(0\)\
\-\ thrombosis\\:\\ 0\\.013053466004103363\ \(0\)\
\-\ on\\:\\ 0\\.012880622995826124\ \(0\)\
\-\ \\(\\:\\ 0\\.012853411499001079\ \(0\)\
\-\ previously\\:\\ 0\\.012774988435065113\ \(0\)\
\-\ \\)\\:\\ 0\\.012696400215539238\ \(0\)\
\-\ limits\\:\\ 0\\.01253456796883276\ \(0\)\
\-\ includes\\:\\ 0\\.012259360839284111\ \(0\)\
\-\ vessels\\:\\ 0\\.012242847033033213\ \(0\)\
\-\ removal\\:\\ 0\\.01198854467010743\ \(0\)\
\-\ 30\\:\\ 0\\.011694268101263611\ \(0\)\
\-\ tumors\\:\\ 0\\.011422478141176159\ \(0\)\
\-\ \\‚\\Ä\\ú\\:\\ 0\\.011357654511669608\ \(0\)\
\-\ \\‚\\Ä\\ù\\:\\ 0\\.011293990580172187\ \(0\)\
\-\ calcification\\:\\ 0\\.011038382983833198\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.01090016293644436\ \(0\)\
\-\ kidney\\:\\ 0\\.010713108380960889\ \(0\)\
\-\ girl\\:\\ 0\\.010691734629856932\ \(0\)\
\-\ inferior\\:\\ 0\\.010317851819783142\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.010279688249096395\ \(0\)\
\-\ possible\\:\\ 0\\.010241929604569652\ \(0\)\
\-\ areas\\:\\ 0\\.010232552210840094\ \(0\)\
\-\ followed\\:\\ 0\\.010195287798500966\ \(0\)\
\-\ size\\:\\ 0\\.010195287798500966\ \(0\)\
\-\ internal\\:\\ 0\\.010195287798500966\ \(0\)\
\-\ initial\\:\\ 0\\.010076804780353409\ \(0\)\
\-\ along\\:\\ 0\\.010050013796649522\ \(0\)\
\-\ study\\:\\ 0\\.0100058055404269\ \(0\)\
\-\ superior\\:\\ 0\\.009710831662114559\ \(0\)\
\-\ adjacent\\:\\ 0\\.009615075601901306\ \(0\)\
\-\ age\\:\\ 0\\.009255908631830272\ \(0\)\
\-\ month\\:\\ 0\\.00912318341921925\ \(0\)\
\-\ decreased\\:\\ 0\\.00904183773211587\ \(0\)\
\-\ demonstrated\\:\\ 0\\.008923202784544367\ \(0\)\
\-\ infection\\:\\ 0\\.008839916633711057\ \(0\)\
\-\ evaluation\\:\\ 0\\.00883359002073597\ \(0\)\
\-\ lung\\:\\ 0\\.008808395445689487\ \(0\)\
\-\ \\,\\:\\ 0\\.008670429144681802\ \(0\)\
\-\ carcinoma\\:\\ 0\\.008618959679771767\ \(0\)\
\-\ cell\\:\\ 0\\.008214379756517745\ \(0\)\
\-\ \\:\\:\\ 0\\.008044660612033202\ \(0\)\
\-\ prior\\:\\ 0\\.007808230506058233\ \(0\)\
\-\ for\\:\\ 0\\.0077840727613101264\ \(0\)\
\-\ metastatic\\:\\ 0\\.007655193607174698\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.007473790169508245\ \(0\)\
\-\ increased\\:\\ 0\\.007439447622062831\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.007330069402072039\ \(0\)\
\-\ noted\\:\\ 0\\.007207904585240546\ \(0\)\
\-\ can\\:\\ 0\\.006897588442950425\ \(0\)\
\-\ case\\:\\ 0\\.006653040686360394\ \(0\)\
\-\ large\\:\\ 0\\.006649617195128397\ \(0\)\
\-\ demonstrates\\:\\ 0\\.006642780077057601\ \(0\)\
\-\ have\\:\\ 0\\.006585188890978974\ \(0\)\
\-\ after\\:\\ 0\\.006291819226367268\ \(0\)\
\-\ also\\:\\ 0\\.005995087521957833\ \(0\)\
\-\ within\\:\\ 0\\.005801179389274312\ \(0\)\
\-\ that\\:\\ 0\\.005252600457504709\ \(0\)\
\-\ by\\:\\ 0\\.005063597520444394\ \(0\)\
\-\ normal\\:\\ 0\\.004767304108893598\ \(0\)\
\-\ from\\:\\ 0\\.004506888658911788\ \(0\)\
\-\ and\\:\\ 0\\.0038436086633213905\ \(0\)\
\-\ or\\:\\ 0\\.0035641378966679983\ \(0\)\
\-\ was\\:\\ 0\\.003517001858411697\ \(0\)\
\-\ this\\:\\ 0\\.00342041712923179\ \(0\)\
\-\ old\\:\\ 0\\.003113646252178842\ \(0\)\
\-\ \\.\\:\\ 0\\.0025266573734766032\ \(0\)\
\-\ of\\:\\ 0\\.0024876256398146997\ \(0\)\
\-\ to\\:\\ 0\\.0015198153325373177\ \(0\)\
\-\ in\\:\\ 0\\.0014996342709617612\ \(0\)\
\-\ the\\:\\ 0\\.001475971011070738\ \(0\)\
\-\ with\\:\\ 0\\.000832769936582845\ \(0\)\
